Ipsen : announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses -Today at 09:36 am

This follows ongoing dialogue with the U.S. FDA regarding the palovarotene NDA review, initiated in May 2021



Paris , Friday 13 August, 2021 - Ipsen today...

Related Keywords

Boston ,Massachusetts ,United States ,Italy ,Paris ,France General ,France ,Canada ,United Kingdom ,Argentina ,Spain ,Brazil ,Saclay ,Cambridge ,Cambridgeshire ,Japan ,Sweden ,China ,Australia ,Shanghai ,American ,Maryann Quinn ,Howard Mayer ,Ipsen Euronext ,Jess Smith ,Drug Administration ,Global Communications ,Data Monitoring Committee ,Drug Development Forum ,Us Communications ,Proc Intl Clin Council ,Business Development ,Head Of Research ,New Drug Application ,Priority Review ,Executive Vice President ,Independent Data Monitoring Committee ,Clementia Pharmaceuticals ,Rare Disease ,Consumer Healthcare ,Total Sales ,Sponsored Leveli American Depositary Receipt ,French Autorit ,Des March ,Development Forum ,Intl Clin Council ,Markets ,